New research from the largest study of its kind details a more comprehensive look at outcomes for COVID-19 patients with AKI, including kidney recovery, the need for dialytic support and post-discharge care.
AKI is a sudden episode of kidney injury or damage, preventing waste from being filtered within the body and can often lead to death.
The outcomes data published in the American Journal of Kidney Disease is a retrospective analysis of electronic health records of 9,657 hospitalized COVID-19 patients between March 1 and April 27, 2020.
The study found that 39.9% (3,854 of 9,657 of patients) developed AKI. While 83.4% (3,216) of those patients did not need kidney replacement therapies, 51.7% (1,663/3,216) survived.
Importantly, the majority of these patients 74.1% saw recovery of kidney function at the time of discharge.
Of patients with AKI who required KRT and survived, 66.7% (72/108) recovered kidney function. In the remaining AKI-KRT patients, a third (36/108) did not have kidney recovery, of which 91.7% who had not previously needed dialysis left the hospitals needing ongoing dialysis care after COVID-19 and AKI.
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.
Home to 50 research labs, 2,500 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine.
We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine a new field of science that has the potential to revolutionise medicine.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA